Prediction of continuous amyloid positron emission tomography with fluid measures of phosphorylated tau and β-amyloid

Brain amyloid-β (Aβ) pathology is a core feature of Alzheimer disease (AD) and can be quantified using positron emission tomography (PET). Cerebrospinal fluid (CSF) and plasma biomarkers detect abnormal Aβ, but it is unclear to what degree they can predict quantitative Aβ-PET. We explored plasma and CSF biomarkers in relation to Aβ-PET in the BioFINDER-2 study (N = 1053), and the BioFINDER-1 study (N = 238). We developed a machine learning pipeline to predict Aβ-PET using CSF and plasma measures. The best models achieved R<sup>2</sup> = 0.79. Plasma P-tau217 and CSF Aβ42/Aβ40 contributed the most. CSF Aβ42/Aβ40 contributed most to identify Aβ-positivity, while continuous Aβ-PET load within the positive range was best predicted by plasma P-tau217. Models using only plasma measures approached performance of CSF models. Altered metabolism of soluble Aβ may be highly associated with presence of Aβ plaques, while soluble P-tau217 levels may continue to change during build-up of Aβ pathology.

Authors

Institutions

Publication Details

Journal
EMBO Molecular Medicine
Published
2025-12-01
DOI
https://doi.org/10.1038/s44321-025-00348-7
Primary Topic
Dementia and Cognitive Impairment Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Prediction of continuous amyloid positron emission tomography with fluid measures of phosphorylated tau and β-amyloid

Randall John Bateman, Sebastian Palmqvist, Erik Stomrud, Kaj Blennow et al.
EMBO Molecular Medicine
Dementia and Cognitive Impairment Research
article

Prediction of continuous amyloid positron emission tomography with fluid measures of phosphorylated tau and β-amyloid

Randall John Bateman, Sebastian Palmqvist, Erik Stomrud, Kaj Blennow, Niklas Mattsson, Oskar Hansson, Nicolas R. Barthélemy, Suzanne E. Schindler, Henrik Zetterberg, Shorena Janelidze, Weizhong Tang, Linda Karlsson
article en

Abstract

Brain amyloid-β (Aβ) pathology is a core feature of Alzheimer disease (AD) and can be quantified using positron emission tomography (PET). Cerebrospinal fluid (CSF) and plasma biomarkers detect abnormal Aβ, but it is unclear to what degree they can predict quantitative Aβ-PET. We explored plasma and CSF biomarkers in relation to Aβ-PET in the BioFINDER-2 study (N = 1053), and the BioFINDER-1 study (N = 238). We developed a machine learning pipeline to predict Aβ-PET using CSF and plasma measures. The best models achieved R<sup>2</sup> = 0.79. Plasma P-tau217 and CSF Aβ42/Aβ40 contributed the most. CSF Aβ42/Aβ40 contributed most to identify Aβ-positivity, while continuous Aβ-PET load within the positive range was best predicted by plasma P-tau217. Models using only plasma measures approached performance of CSF models. Altered metabolism of soluble Aβ may be highly associated with presence of Aβ plaques, while soluble P-tau217 levels may continue to change during build-up of Aβ pathology.

EMBO Molecular MedicineVol. 18(1)
University of Science and Technology of China (CN), University of Wisconsin–Madison (US), Lund University (SE), Washington University in St. Louis (US), Sahlgrenska University Hospital (SE), Sorbonne Université (FR), Pitié-Salpêtrière Hospital (FR), UK Dementia Research Institute (GB), Skåne University Hospital (SE), Institut du Cerveau (FR), University College London (GB), University of Gothenburg (SE)
Openalex Percentile: Top 56%
Dementia and Cognitive Impairment Research
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.